• Medtronic released its fiscal 2026 Impact Report, citing more than 82 million patients served worldwide.
• R&D investment totaled $2.9 billion, supporting more than 315 product approvals in major markets, including FDA clearance of the Hugo surgical robot.
• Quality nonconformances fell 70% through expanded First Time Quality programs across manufacturing, distribution, and service operations.
• Scope 1 and 2 emissions intensity dropped 68% versus the fiscal 2020 baseline; renewable electricity sourcing rose to 65%.
• Supplier engagement on Scope 3 targets increased to about 18%; packaging materials fell by 230 tonnes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.